New Rhein

New Rhein helps life sciences companies advance later-stage, de-risked therapeutics and medical devices to market. The firm combines private equity and venture capital with hands-on operational executives, deal-making, and a network to support development, regulatory, and commercialization. Its focus spans COPD, BPH, COVID-19, migraine and other indications, leveraging core drug and device platforms and strategy-driven exits. With trans-Atlantic offices in Philadelphia and Mechelen, New Rhein assists portfolio companies through manufacturing, reimbursement strategies, and partnerships.